KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Acquisitions (2016 - 2019)

Abbott Laboratories' Acquisitions history spans 11 years, with the latest figure at $82.0 million for Q2 2019.

  • For Q2 2019, Acquisitions rose 355.56% year-over-year to $82.0 million; the TTM value through Jun 2019 reached $203.0 million, down 95.17%, while the annual FY2017 figure was $17.2 billion, 21378.75% up from the prior year.
  • Acquisitions for Q2 2019 was $82.0 million at Abbott Laboratories, up from $78.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $13.0 billion in Q1 2017 and bottomed at $7.0 million in Q4 2016.
  • The 5-year median for Acquisitions is $78.0 million (2019), against an average of $2.0 billion.
  • The largest annual shift saw Acquisitions soared 59271.43% in 2017 before it tumbled 99.81% in 2018.
  • A 5-year view of Acquisitions shows it stood at $231.0 million in 2015, then tumbled by 96.97% to $7.0 million in 2016, then skyrocketed by 59271.43% to $4.2 billion in 2017, then crashed by 99.57% to $18.0 million in 2018, then soared by 355.56% to $82.0 million in 2019.
  • Per Business Quant, the three most recent readings for ABT's Acquisitions are $82.0 million (Q2 2019), $78.0 million (Q1 2019), and $18.0 million (Q2 2018).